What is the role of glycosaminoglycans (GAGs) in treating degenerative joint conditions?

Glycosaminoglycans (GAGs) play a crucial role in the management of degenerative joint conditions primarily as chondroprotective agents. This means they help in protecting cartilage from further degradation and promote its repair. GAGs are major components of the extracellular matrix in cartilage, and they contribute to the structural integrity and resilience of cartilage tissue.

By providing lubrication and a supportive environment for cartilage cells, GAGs can help to inhibit the breakdown of cartilage, promote cell proliferation, and enhance the synthesis of cartilage matrix components. This chondroprotective property is essential in managing degenerative conditions such as osteoarthritis, as it can help slow the progression of the disease and maintain joint health.

While GAGs have some secondary benefits that could relate to reducing inflammation or improving mobility, their primary mechanism of action in therapy revolves around protecting and maintaining healthy cartilage. This chondroprotective function distinguishes their role specifically in the context of treating degenerative joint diseases.